Entera Bio Ltd., a renowned pioneer in the research and development of orally delivered peptides and minor therapeutic proteins, has recently announced that it will present the promising data from the Phase 1 study of PTH(1-34) Peptide Tablets (EB612) ’ an innovative first-in-class treatment for hypoparathyroidism ’ at the prestigious Endocrine Society’s Annual Meeting, ENDO 2024. The event, which draws a significant number of experts and researchers from the world of endocrinology, will take place from June 1-4, 2024 in Boston, Massachusetts.
Entera Bio’s EB612 is the first orally administered, synthetic human parathyroid hormone fragment (1-34) designed for the treatment of hypoparathyroidism, a condition characterized by diminished production of parathyroid hormone, resulting in abnormal calcium and phosphorus metabolism. Current treatments for this disorder are typically intravenous or subcutaneous injections, making the oral formulation of EB612 a potential groundbreaker in this area of treatment.
The Phase 1 data presentation at ENDO 2024 is a critical milestone in the development timeline of EB612. The presentation will include specifics about the safety, tolerability, effectiveness and pharmacokinetic parameters of the drug. This will provide crucial insights for the future stages of clinical trials, crafting a pathway for the development of an effective and dependable oral therapy for hypoparathyroidism.
The selection of Entera Bio’s investigational program EB612 by the Endocrine Society for presentation at its annual meeting provides the product with an exceptional stage to showcase its potential value to the medical and scientific community. This exposure might lead to strategic partnerships, collaborations, or investment opportunities for the company; subsequently accelerating further development of the oral peptide tablet.
The team at Entera Bio has expressed their excitement at the opportunity to share the progress made with EB612, and the potential it holds in transforming the treatment landscape of hypoparathyroidism. That EB612 is making this critical leap from the laboratory to the podium of ENDO 2024 signals how this pioneering oral formulation can reshape the therapeutic approach to alternative bioavailable PTH treatments.
Overall, the promising performance of EB612 in the Phase 1 trials has generated significant enthusiasm around its potential to enhance the treatment paradigm of hypoparathyroidism. The unveiling of these trial results at the esteemed Endocrine Society Annual Meeting, ENDO 2024, will indeed be a pivotal moment in the development history of this disruptive oral peptide therapy.
Comments